Read more stories about
Incubators and R&D >>

MATR Sponsor:

MATR Supporters:

Precision Medicine May Be Health Care's Next Big Thing, But We Don't Yet Know How to Evaluate Precision Drugs

November 9, 2016View for printing

Finally, there's a drug available to treat Duchenne muscular dystrophy, a rare, fatal genetic muscle-wasting disease that grips roughly 10,000 people, mostly boys, in the U.S., who are unlikely to live into their 30s and typically lose the ability to walk in adolescence.

Full Story: ... healthit_nl
No reader comments so far. Be the first to comment by clicking the button below.

Reprinted under the Fair Use doctrine of international copyright law. Full copyright retained by the original publication. In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

E-mail this page to a friend!